Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 3
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
3| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9573964 | VONJOpacritinib citrate | use | May 2028 |
| 8153632 | VONJOpacritinib citrate | substance, product | Jan 2029 |
| 8980873 | VONJOpacritinib citrate | substance, product | Mar 2030 |
| Product | Exclusivity | Until |
|---|---|---|
| VONJOPACRITINIB CITRATE | ODE-397 Orphan drug | Feb 2029 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Vonjo | Pacritinib | capsule, oral | 72482-100NDA |
Enquiry
Common questions
- Is Sobi, Inc. FDA approved?
- Sobi, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Sobi, Inc. make?
- 1 product is listed under Sobi, Inc. in the openFDA NDC Directory, most often as capsule. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.